Celyad grants Novartis a non-exclusive license

2 May 2017

Belgian biotech firm Celyad (Euronext Brussels: CYAD) has signed a non-exclusive license agreement with Novartis (NOVN: VX) for Celyad’s US patents for the production of allogeneic CAR-T cells.

This agreement is related to two targets currently under development by Novartis, which (along with Kite) is also in the race to bring the first CAR-T therapy to market, with its Biologics License Application for CTL019 already under priority review at the US Food and Drug Administration. News of the deal pushed Celyad’s share up 10.7% to 32.48 euros by late-morning trading today.

The agreement includes Celyad’s intellectual property rights under US Patent No 9,181,527 related to allogeneic human primary T-Cells that are engineered to be T-Cell receptor (TCR) deficient and express a chimeric antigen receptor (CAR). The granted claims are not limited to specific CARs or specific methods of generating allogeneic CAR T- cells, such as genome editing or genetic engineering.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK